Relative Effects of Time-Restricted Eating, Energy-Restricted Eating, and Unrestricted Eating on Eating Patterns and Dietary Intake: Results From a Randomized Controlled Trial.

J Acad Nutr DietMar 16, 2026 (epub)
Clinical ResearchEndocrinologyGastroenterologyOpen access

Lisa J Harnack, Niki Oldenburg, Qi Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized controlled trial examined eating patterns and dietary intake among adults with obesity assigned to time-restricted eating (TRE), energy-restricted eating (ER), or unrestricted eating (UE). Of 88 randomized participants, 73 completed baseline and follow-up dietary measures. After 12 weeks, the TRE group reported 1.1 fewer meals per day than at baseline (95% CI, -1.6, -0.7), alongside reductions in energy and several dietary components. Changes in intake did not differ significantly between TRE and ER, while some reductions were more marked with TRE than UE.

Key findings

  • TRE participants reported 1.1 fewer meals/day at follow-up than baseline (95% CI, -1.6, -0.7); ER and UE groups showed no change in eating occasions.
  • Breakfast reporting declined in the TRE group (OR, 0.13; 95% CI, 0.05, 0.33), with no statistically significant change in ER or UE.
  • In TRE, energy intake decreased by -469 kcal/day (95% CI, -681, -257), with reductions also reported in saturated fat, potassium, and total and refined grains.
  • Dietary intake changes did not differ significantly between TRE and ER; several reductions were more marked with TRE than UE.

Why it matters

Eating schedules can alter not only meal frequency but also reported nutrient and food-group intake. These findings suggest that an 8-hour TRE approach may produce dietary changes resembling those seen with energy restriction, while also reducing intake of some nutrients and food groups. Monitoring overall dietary adequacy may therefore be relevant when evaluating time-restricted eating.

What to keep in mind

This was a secondary analysis, and dietary measures were available for 73 of the 88 randomized participants. The intervention lasted 12 weeks, limiting conclusions about longer-term dietary patterns.

Source

Published in J Acad Nutr Diet. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.